Found: 25
Select item for more details and to access through your institution.
NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 389, doi. 10.1007/s10637-013-0039-4
- By:
- Publication type:
- Article
Successful readministration of trastuzumab after severe immune reactions in two breast cancer patients.
- Published in:
- 2014
- By:
- Publication type:
- Report
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 569, doi. 10.1007/s10637-013-0052-7
- By:
- Publication type:
- Article
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 561, doi. 10.1007/s10637-014-0075-8
- By:
- Publication type:
- Article
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 452, doi. 10.1007/s10637-013-0047-4
- By:
- Publication type:
- Article
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 481, doi. 10.1007/s10637-013-0055-4
- By:
- Publication type:
- Article
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 510, doi. 10.1007/s10637-013-0062-5
- By:
- Publication type:
- Article
Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 489, doi. 10.1007/s10637-013-0050-9
- By:
- Publication type:
- Article
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 555, doi. 10.1007/s10637-014-0074-9
- By:
- Publication type:
- Article
Phase II trial of vorinostat in advanced melanoma.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 526, doi. 10.1007/s10637-014-0066-9
- By:
- Publication type:
- Article
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 500, doi. 10.1007/s10637-013-0060-7
- By:
- Publication type:
- Article
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 436, doi. 10.1007/s10637-013-0046-5
- By:
- Publication type:
- Article
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 518, doi. 10.1007/s10637-014-0064-y
- By:
- Publication type:
- Article
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 465, doi. 10.1007/s10637-013-0051-8
- By:
- Publication type:
- Article
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 445, doi. 10.1007/s10637-013-0044-7
- By:
- Publication type:
- Article
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 400, doi. 10.1007/s10637-013-0043-8
- By:
- Publication type:
- Article
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 412, doi. 10.1007/s10637-013-0041-x
- By:
- Publication type:
- Article
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 549, doi. 10.1007/s10637-014-0073-x
- By:
- Publication type:
- Article
Radiosensitizing activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 424, doi. 10.1007/s10637-014-0079-4
- By:
- Publication type:
- Article
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 535, doi. 10.1007/s10637-014-0065-x
- By:
- Publication type:
- Article
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 542, doi. 10.1007/s10637-014-0070-0
- By:
- Publication type:
- Article
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 473, doi. 10.1007/s10637-013-0056-3
- By:
- Publication type:
- Article